ArticleBreast cancer (Tokyo, Japan)2025

Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study.

Yosuke Aoyama et al.PubMed ↗Publisher ↗

No numbers read from the abstract.